Excretion of fluvoxamine into breast milk

Hägg, Staffan; Granberg, Kerstin; Carleborg, Lena

doi:10.1046/j.1365-2125.2000.00142-3.x

Cited by 38 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…the concentration of the drug in the infant was minimal or undeteetable for fluoxetine (67)(68)(69)(70)(71)(72)(73)(74), paroxetine (75)(76)(77)(78)(79), sertraline (74,79 81,83-85,87). fluvoxamine (75,(89)(90)(91)(92) or citalopram (93)(94)(95)(96)(97), Moreover, when mother was taking therapeutic doses of sertraline, serotonin transporter bloekade in the fetus was found to be far lower than would be expected from that observed in the mother, suggesting that clinical doses of sertraline in the mother do not appreciably affect the fetus (81). Similarly Wisner et al (98) and Birnbaum et al (99) have critically reviewed the literature and reported that tricylie antidepressants were found in negligible quantities in breast fed infants.…”

Section: Amidepressants and Breastfeedingmentioning

confidence: 83%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

About 20% of pregnant women experience clinical depression. Inadequate treatment of depression has been associated with adverse outcomes in the mother as well as the newborn. Clinicians are often uncertain about pharmacological interventions to treat depressed pregnant women due to concerns regarding fetal exposure to medications. Moreover newer antidepressants with different pharmacological profiles and little data on fetal risk continue to be introduced at a brisk pace. Accumulating data from pharmaceutical registries, cohort studies, toxicology centers, some prospective studies, and case series have permitted certain guidelines for antidepressant use during pregnancy. We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy.

show abstract

Section: Amidepressants and Breastfeedingmentioning

confidence: 83%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

“…59,60,65,66,67 In 2 infants, the plasma drug level was measured and was not detectable. 66,67 Only in 1 of the 7 infants a possible adverse event was noted.…”

Section: Fluvoxaminementioning

confidence: 99%

“…(J Clin Psychopharmacol 2005;25: [59][60][61][62][63][64][65][66][67][68][69][70][71][72][73] A n estimated 8% to 20% of all women develop clinical symptoms of depression at some time during their lives, for which drug therapy is often required. 1,2 In addition, mood disorders and anxiety disorders such as depression, panic disorder, and obsessive-compulsive disorder are common in women during their childbearing years, 3 which increases the likelihood of potential need for antidepressants during pregnancy.…”

mentioning

confidence: 99%

The Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Breast-feeding

Hallberg

Sjöblom

2005

Journal of Clinical Psychopharmacology

106

View full text Add to dashboard Cite

Mood and anxiety disorders are common in women during their childbearing years. The prevalence of depression has been reported to be between 10% and 16% during pregnancy. The use of selective serotonin reuptake inhibitors during pregnancy or lactation is, to date, not promoted because of lack of safety documentation. However, the off-label use of these drugs has been common for several years. In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose. This has created concern among women planning pregnancies and pregnant women, as well as among their families and physicians. Several studies and reports of the use of serotonin reuptake inhibitors during both pregnancy and lactation have been published and advanced our knowledge. We here review and discuss those studies which have been published so far on this subject.

show abstract

“…All SSRIs have been detected in breast milk, although paroxetine 31-33 and sertraline 33-38 usually produced undetectable infant serum levels. 30 There are virtually no case reports of escitalopram and few case reports of fluvoxamine [47][48][49][50][51][52] in nursing mothers, most likely because escitalopram is only recently available and fluvoxamine was indicated for obsessive compulsive disorder, not depression, and therefore is not used as frequently. In contrast, fluoxetine, [39][40][41][42][43][44] in 22% of cases, and citalopram, 33,45,46 in 17% of cases, have exceeded the 10% maternal level.…”

Section: Risks and Benefits Of Antidepressant Treatment In Lactating mentioning

confidence: 99%

Use of Antidepressants in Nursing Mothers

2011

Breastfeeding

View full text Add to dashboard Cite

Excretion of fluvoxamine into breast milk

Cited by 38 publications

References 15 publications

Pharmacotherapy of Depression in Pregnancy

Pharmacotherapy of Depression in Pregnancy

The Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Breast-feeding

Use of Antidepressants in Nursing Mothers

Contact Info

Product

Resources

About